Kathy S. Albain, MD, FACP, FASCO
Professor of Medicine, Division of Hematology/Oncology
Stritch School of Medicine of Loyola University Chicago
Huizenga Family Endowed Chair in Oncology Research
Director, Breast Clinical Research and Thoracic Oncology Programs
Cardinal Bernardin Cancer Center
Loyola University of Chicago
Developing strategies to block the survival of dormant breast cancer stem cells in order to improve patient outcomes.
Development of drugs resistance remains a clinical challenge. Breast cancer stem cells (BCSCs), are the tumor cells most likely to survive anti-cancer therapies and cause breast cancer recurrence many years later. Drs. Albain and Osipo are focused on defining the mechanisms involved in BCSC survival that may be targeted to prevent treatment resistance. They have identified key pathways involved in the resistance of BCSCs to cancer treatment as well as a gene called DAXX, a potent inhibitor of BCSCs. They have shown that high amounts of the DAXX gene correlates with a reduction in the number of BCSCs and a better response to endocrine therapy, standard chemotherapy, and PARP inhibitor treatment in ER-positive and TNBC cells. Further work has the potential inform the development of new strategiesto reduce drug resistance in ER-positive and TNBC.
Drs. Albain and Osipo have shown that increasing DAXX levels in breast cancer cells effectively kills all breast cancer cells including BCSCs. In the past year, they found: high levels of the DAXX gene inhibited endocrine therapy-associated resistance in ER-positive breast cancer cells; and DAXX status also predicted sensitivity to chemotherapy, DNA damage response, and PARP inhibition in TNBC cells. The team has collected breast cancer biopsies before and after pre-surgical (neoadjuvant) endocrine therapy or chemotherapy and examined the levels of DAXX and other biomarkers. They are now correlating the biomarker status with response to neoadjuvant therapy.
Going forward, they will utilize a large national tumor biorepository to validate their results regarding the potential for DAXX and other biomarkers to predict response to endocrine therapy for ER-positive breast cancer and/or chemotherapy for TNBC. They will also investigate the mechanism by which DAXX turns off BCSC genes to identify strategies to target BCSCs and decrease breast cancer resistance to treatment.
Kathy S. Albain is Professor of Medicine (tenured) at Loyola University Chicago Stritch School of Medicine and is a Dean’s Senior Scholar. As a member of the Division of Hematology/Oncology, she devotes her clinical practice to patients with breast and lung cancer at Loyola’s Cardinal Bernardin Cancer Center. She is Co-leader of the Breast Cancer Program (with Clodia Osipo, PhD), Director of the Breast Clinical Research Program, Co-director of the multidisciplinary Breast Oncology Center, and Director of the Thoracic Oncology Program.
Dr. Albain is involved in national research and advisory activities pertaining to breast and lung cancers as well as cancer survivorship and special populations research. She chaired the Committee on Special Populations for SWOG, an NCI cooperative group, from its inception. This committee conducted novel research that addressed gender differences in cancer, survivorship issues, and outcome and treatment of special populations. A lay advocates program was formed under her leadership. Following SWOG reorganization, Dr. Albain served as co-chair of its Cancer Survivorship Committee. She also co-chairs an international breast cancer survivorship collaboration. Dr. Albain is a member of the SWOG working groups for breast and lung cancer. She is a member of the international Early Breast Cancer Trialists’ Collaborative Group and Steering Committee. She was a charter member of the NIH Committee on Research on Women’s Health and completed a term on the FDA Oncologic Drugs Advisory Committee (ODAC). She has over 170 publications in peer-reviewed journals and major textbooks, and is a Fellow of the American College of Physicians.
When you give to BCRF, you're funding critical hours in the lab. More time for research means longer, healthier lives for the ones we love.